Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -135.50% is 123% below its 5-year average of -60.83%, around the middle of its 5-year range (-212.17%–-19.53%).
As of the fiscal period ended Tuesday, June 30, 2026. 7.39% below its 12-month average of -126.18%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -135.50%.
RETURN ON EQUITY (ROE)
-135.50%
RETURN ON EQUITY (ROE) AVG TTM
-126.18%
RETURN ON EQUITY (ROE) AVG 3Y
-60.44%
RETURN ON EQUITY (ROE) AVG 5Y
-60.83%
RETURN ON EQUITY (ROE) AVG 10Y
-56.42%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-7.39%
CURRENT VS 3Y AVG
-124.18%
CURRENT VS 5Y AVG
-122.75%
CURRENT VS 10Y AVG
-140.19%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-222.55%
vs the sector median at left
Larimar Therapeutics, Inc.
Market Cap
$291.39M
Return on Equity (ROE)
-135.50%
TTM Avg
-126.18%
3Y Avg
-60.44%
5Y Avg
-60.83%
Market Cap
$291.03M
Return on Equity (ROE)
-135.62%
TTM Avg
-521.17%
3Y Avg
-307.05%
5Y Avg
43.03%
Market Cap
$285.58M
Return on Equity (ROE)
-18.38%
TTM Avg
-37.53%
3Y Avg
-22.34%
5Y Avg
-10.93%
Market Cap
$286.36M
Return on Equity (ROE)
-16.18%
TTM Avg
-23.55%
3Y Avg
59.17%
5Y Avg
22.66%
Market Cap
$285.83M
Return on Equity (ROE)
-49.11%
TTM Avg
-50.02%
3Y Avg
-153.47%
5Y Avg
-149.41%
Market Cap
$301.29M
Return on Equity (ROE)
-25.73%
TTM Avg
-32.35%
3Y Avg
-2448.72%
5Y Avg
-1749.34%
Market Cap
$283.18M
Return on Equity (ROE)
-56.36%
TTM Avg
-35.98%
3Y Avg
25430.43%
5Y Avg
20391.58%
Market Cap
$283.69M
Return on Equity (ROE)
-21.41%
TTM Avg
-11.72%
3Y Avg
-50.56%
5Y Avg
-98.46%
Market Cap
$303.90M
Return on Equity (ROE)
N/A
TTM Avg
30.84%
3Y Avg
30.84%
5Y Avg
30.84%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | $291.39M | -135.50% | -126.18% | -60.44% | -60.83% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $291.03M | -135.62% | -521.17% | -307.05% | 43.03% |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.58M | -18.38% | -37.53% | -22.34% | -10.93% |
| Standard BioTools Inc. (LAB)vs › | $286.36M | -16.18% | -23.55% | 59.17% | 22.66% |
| Abeona Therapeutics Inc. (ABEO)vs › | $285.83M | -49.11% | -50.02% | -153.47% | -149.41% |
| Benitec Biopharma Inc. (BNTC)vs › | $301.29M | -25.73% | -32.35% | -2448.72% | -1749.34% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $283.18M | -56.36% | -35.98% | 25430.43% | 20391.58% |
| Aurora Cannabis Inc. (ACB)vs › | $283.69M | -21.41% | -11.72% | -50.56% | -98.46% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $303.90M | N/A | 30.84% | 30.84% | 30.84% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | -27.36% | -12.73% | -30.52% | -39.12% |
ROE
-135.5%
ROA
-104.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -135.50% |
| 2026-03-31 | -105.04% |
| 2025-12-31 | -212.17% |
| 2025-09-30 | -94.94% |
| 2025-06-30 | -83.26% |
| 2025-03-31 | -66.01% |
| 2024-12-31 | -46.91% |
| 2024-09-30 | -32.65% |
| 2024-06-30 | -27.60% |
| 2024-03-31 | -19.53% |
| 2023-12-31 | -45.21% |
| 2023-09-30 | -36.01% |
| 2023-06-30 | -32.66% |
| 2023-03-31 | -31.00% |
| 2022-12-31 | -31.88% |
| 2022-09-30 | -29.55% |
| 2022-06-30 | -87.00% |
| 2022-03-31 | -83.16% |
| 2021-12-31 | -78.61% |
| 2021-09-30 | -77.30% |
| 2021-06-30 | -72.82% |
| 2021-03-31 | -60.79% |
| 2020-12-31 | -47.36% |
| 2020-09-30 | -33.47% |
| 2020-06-30 | -29.06% |
| 2020-03-31 | -49.43% |
| 2019-09-30 | -44.93% |
| 2019-06-30 | -46.22% |
| 2018-12-31 | -65.80% |
| 2018-09-30 | -57.61% |
| 2018-06-30 | -110.34% |
| 2018-03-31 | -84.58% |
| 2017-12-31 | -66.52% |
| 2017-09-30 | -55.34% |
| 2017-06-30 | -51.67% |
| 2017-03-31 | -47.98% |
| 2016-12-31 | -47.55% |
| 2016-09-30 | -54.25% |
| 2016-06-30 | -53.31% |
| 2016-03-31 | -50.87% |
| 2015-12-31 | -43.93% |
